Literature DB >> 3802640

Pseudoallescheria boydii soft tissue abscess.

T G Sheftel, J T Mader, G Cierny.   

Abstract

Pseudoallescheria boydii, a fungus often isolated from soil, commonly causes a mycetoma. Successful treatment involves resection of the infected area and appropriate antifungal chemotherapy. In vitro sensitivity of P. boydii to miconazole is usually demonstrated, but resistance to amphotericin B and 5-fluorocytosine is often observed. Limited data are available on the treatment of this infection with ketoconazole. An usual case of nontraumatic P. boydii soft tissue infection without draining sinus tracts occurred in a 50-year-old woman. Nontraumatic P. boydii soft tissue infection was diagnosed by cytologic preparation and fungal cultures of the aspirate. The patient was successfully treated with en bloc resection for four months of oral ketoconazole.

Entities:  

Mesh:

Year:  1987        PMID: 3802640

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Subcutaneous pseudallescheriasis in a renal transplant recipient.

Authors:  J O Lopes; S H Alves; J P Benevenga; A Salla; C Khmohan; C B Silva
Journal:  Mycopathologia       Date:  1994-03       Impact factor: 2.574

Review 2.  Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.

Authors:  Joanna M Schaenman; Daniel B DiGiulio; Laurence F Mirels; Nancy M McClenny; Gerald J Berry; Annette W Fothergill; Michael G Rinaldi; Jose G Montoya
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

Review 3.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.